Indivumed will analyze various biomarkers and drug targets in the area of oncology for Roche Diagnostics. This should enable Roche to efficiently develop novel targeted therapies for cancer, the companies note.
Indivumed will apply its automated immunohistochemistry (IHC) service platform. It will also provide a selection of tumor tissue sections from its tumor biobank as well as specifically collected clinical samples.
Indivumed currently has a tumor biobank of over 6,500 patient cases, the company reports. It is a resource for the firm’s internal cancer research in biomarkers and primary cell drug screening as well as for for pharmaceutical and biopharma partners through tumor biobank access and IHC services.